Company Participation - SI-BONE, Inc. will participate in the 2025 Goldman Sachs 46 Global Healthcare Conference in Miami Beach, FL, hosting a fireside chat on June 10, 2025, at 8:20 a.m. Pacific Time [1] Company Overview - SI-BONE is a global leader in developing technologies for surgical treatment of sacropelvic disorders, having pioneered minimally invasive SI joint surgery in 2009 with the iFuse Implant System [3] - The company has supported over 4,500 physicians in performing more than 120,000 procedures, backed by over 160 peer-reviewed publications, including two randomized controlled trials [3] - SI-BONE has expanded its offerings to adjacent markets, including adult deformity, spinopelvic and sacropelvic fixation, and pelvic trauma [3]

Company Overview - SI-BONE, Inc. is a medical device company focused on addressing sacropelvic disorders and is recognized as a global leader in developing surgical technologies for these conditions [3] - The company pioneered minimally invasive SI joint surgery in 2009 and has supported over 4,500 physicians in performing more than 120,000 procedures [3] - SI-BONE has established a strong clinical evidence base, including two randomized controlled trials and over 160 peer-reviewed publications [3] Upcoming Event - SI-BONE will participate in the 2025 BofA Securities Healthcare Conference in Las Vegas, with a fireside chat scheduled for May 13, 2025, at 8:40 a.m. Pacific Time [1] - Investors can listen to the conference call by registering online, and a live audio webcast will be available on the company's website [2]

Financial Performance - SI-BONE achieved a worldwide revenue growth of 24.9% reaching $47.3 million in 1Q25[8] - U S revenue grew by 26.6% to $44.8 million in 1Q25[8] - The company reported a gross margin of 79.7%, an improvement of 80 basis points[8] - Adjusted EBITDA turned positive at $0.5 million, a 112% year-over-year improvement[8, 15] - The company expects to have $144.4 million in cash and equivalents[16] Physician Engagement and Procedure Volume - SI-BONE added a record 300 U S physicians in 1Q25[6] - There was a 27.1% growth in U S active physicians[8] - U S procedure volume increased by approximately 27% from 4,000 in 1Q24 to 5,100 in 1Q25[10] - The U S active physician base grew by approximately 27% from 1,100 in 1Q24 to 1,400 in 1Q25[12] Product and Market Opportunity - The company is developing a third breakthrough-designated device, iFuse TORQ TNT[6] - SI-BONE is pursuing a proposed New Technology Add-On Payment (NTAP) of $3,960 for iFuse TORQ TNT[6] - The total U S addressable market for SI-BONE's products is estimated to be over $3.5 billion, with less than 10% currently penetrated[21, 29] Future Outlook - The company updated its 2025 worldwide revenue guidance to $193.5 - $197.5 million, implying a growth of approximately 16%-18%[19, 20]

Core Insights - SI-BONE, Inc. will report its financial results for Q1 2025 on May 5, 2025, after market close, with a conference call scheduled for 1:30 p.m. Pacific Time [1] - The company is a leader in developing technologies for surgical treatment of sacropelvic disorders, having supported over 4,300 physicians and performed over 115,000 procedures since 2009 [3] Company Overview - SI-BONE has pioneered minimally invasive SI joint surgery and has a strong clinical evidence base, including two randomized controlled trials and over 160 peer-reviewed publications [3] - The company has expanded its offerings to adjacent markets, including adult deformity, sacropelvic fixation, and pelvic trauma [3] Investor Information - Investors can listen to the conference call by registering online, and a live audio webcast will be available on the company's website [2] - The webcast will be archived for at least 90 days for replay [2]